2009
DOI: 10.1016/j.lungcan.2008.04.001
|View full text |Cite
|
Sign up to set email alerts
|

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
75
0
5

Year Published

2014
2014
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 136 publications
(80 citation statements)
references
References 31 publications
0
75
0
5
Order By: Relevance
“…In these reports vinorelbine was well tolerated being the main side effects grade 3-4 neutropenia (range, 8-55%), anemia (17%), constipation (8-12%) and peripheral neuropathy (11%) (12)(13)(14).…”
Section: Vinorelbinementioning
confidence: 95%
“…In these reports vinorelbine was well tolerated being the main side effects grade 3-4 neutropenia (range, 8-55%), anemia (17%), constipation (8-12%) and peripheral neuropathy (11%) (12)(13)(14).…”
Section: Vinorelbinementioning
confidence: 95%
“…In salvage treatment, with the combination of gemcitabine and vinorelbine, the disease stabilization was 37%, the response rate was 7.4%, and the median progression-free survival was 2.8 months (Zucali et al, 2006). In a phase II study in which 63 patients were administered single agent vinorelbinin, the response rate was 16% and the overall survival was 9.6 months (Stebbing et al, 2009). Nowadays, although there is no standardized treatment regime which has been proven to be useful for survival in secondary care, in clinical practice, the patients with epiteloid MPM who are young and have good performance status are increasingly being treated by secondary care treatments (Ceresoli et al, 2011).…”
Section: Discussionmentioning
confidence: 99%
“…To date, single agent-based CT is an accepted practice, based upon phase II studies demonstrating improved response rates with gemcitabine, vinorelbine or anthracyclines (44)(45)(46)(47). The combination of cisplatingemcitabine (48), irinotecan-cisplatin-mitomycin (49), and oxaliplatin-raltitrexed (50,51), have also been evaluated as second-line approaches.…”
Section: Second-line Treatment With Single-agent Ctmentioning
confidence: 99%